← Russell 3000 cross-section

BBIO BridgeBio Pharma, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-10, not restated
Healthcare

Scale

Market cap
$15.4bn
Revenue TTM
$713m
Net income TTM
$-702m
Free cash flow
$-435m
Composite score
29.7
Sector rank
#532

Valuation

P / E
EV / EBITDA
EV / sales
24.3
FCF yield
-2.83%
Earnings yield vs 10-yr
-9.30pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-98.5%
EBITDA margin
-69.1%
ROE
27.9%
ROIC
Revenue growth
202.4%

Insider activity, last 90 days

Net open-market
$-33.00m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Under the 2026 ATM Agreement, we have agreed to pay the 2026 ATM Sales Agents a customary commission of up to 3.0% of the aggregate gross proceeds from all sales of the common stock. The Royalty Agreement Purchasers’ rights to the Purchased Royalty Payment are subject to (a) an annual cap equal to 60% of all royalty payments paid by Bayer to Eidos and its affiliates under the Bayer License Agreement on the first $500.0 million of annual net sales of Licensed Products in the Licensed Territory under the Bayer License Agreement and (b) an initial hard cap equal to 145% of the Purchase Price. …BridgeBio Pharma, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-10

Read the full passage →